Tumour Fatty Acid Metabolism in the Context of Therapy Resistance and Obesity

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2021 Aug 21

PMID 34417571

Citations 149

Authors

Andrew J Hoy

Shilpa R Nagarajan

Lisa M Butler

Affiliations

Soon will be listed here.

Abstract

Fatty acid metabolism is known to support tumorigenesis and disease progression as well as treatment resistance through enhanced lipid synthesis, storage and catabolism. More recently, the role of membrane fatty acid composition, for example, ratios of saturated, monounsaturated and polyunsaturated fatty acids, in promoting cell survival while limiting lipotoxicity and ferroptosis has been increasingly appreciated. Alongside these insights, it has become clear that tumour cells exhibit plasticity with respect to fatty acid metabolism, responding to extratumoural and systemic metabolic signals, such as obesity and cancer therapeutics, to promote the development of aggressive, treatment-resistant disease. Here, we describe cellular fatty acid metabolic changes that are connected to therapy resistance and contextualize obesity-associated changes in host fatty acid metabolism that likely influence the local tumour microenvironment to further modify cancer cell behaviour while simultaneously creating potential new vulnerabilities.

Citing Articles

Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis.

Huang L, Xu R, Chen S, Lin C, Li W, Li S Mol Cancer. 2025; 24(1):73.

PMID: 40059153 PMC: 11892139. DOI: 10.1186/s12943-025-02274-1.

SPICE1 promotes osteosarcoma growth by enhancing the deubiquitination of FASN mediated by USP10.

Tong W, Xie X, Shu Z, Nie J, Yang X, Yang F J Transl Med. 2025; 23(1):220.

PMID: 39985078 PMC: 11846344. DOI: 10.1186/s12967-025-06248-1.

Reprogramming of fatty acid metabolism: a hidden force regulating the occurrence and progression of cholangiocarcinoma.

Zhang J, Ruan K, Chu Z, Wang X, Gu Y, Jin H Cell Death Discov. 2025; 11(1):72.

PMID: 39984452 PMC: 11845788. DOI: 10.1038/s41420-025-02351-w.

Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation.

Liu J, Shen Y, Liu J, Xu D, Chang C, Wang J Nat Commun. 2025; 16(1):1762.

PMID: 39971971 PMC: 11839913. DOI: 10.1038/s41467-025-57099-9.

Analysis of fatty acid metabolism in prostate cancer and discovery of a new programmed cell death-associated luminal cell subpopulation.

Zeng Y, Jiang Z Discov Oncol. 2025; 16(1):194.

PMID: 39961915 PMC: 11832849. DOI: 10.1007/s12672-025-01982-w.

References

Faubert B, Solmonson A, DeBerardinis R . Metabolic reprogramming and cancer progression. Science. 2020; 368(6487). PMC: 7227780. DOI: 10.1126/science.aaw5473. View

Balaban S, Lee L, Varney B, Aishah A, Gao Q, Shearer R . Heterogeneity of fatty acid metabolism in breast cancer cells underlies differential sensitivity to palmitate-induced apoptosis. Mol Oncol. 2018; 12(9):1623-1638. PMC: 6120225. DOI: 10.1002/1878-0261.12368. View

Balaban S, Nassar Z, Zhang A, Hosseini-Beheshti E, Centenera M, Schreuder M . Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. Mol Cancer Res. 2019; 17(4):949-962. DOI: 10.1158/1541-7786.MCR-18-0347. View

Balaban S, Shearer R, Lee L, van Geldermalsen M, Schreuder M, Shtein H . Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab. 2017; 5:1. PMC: 5237166. DOI: 10.1186/s40170-016-0163-7. View

Li H, Ning S, Ghandi M, Kryukov G, Gopal S, Deik A . The landscape of cancer cell line metabolism. Nat Med. 2019; 25(5):850-860. PMC: 6629041. DOI: 10.1038/s41591-019-0404-8. View

Chen P, Cai L, Huffman K, Yang C, Kim J, Faubert B . Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Mol Cell. 2019; 76(5):838-851.e5. PMC: 6898782. DOI: 10.1016/j.molcel.2019.08.028. View

Hakimi A, Reznik E, Lee C, Creighton C, Brannon A, Luna A . An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 2016; 29(1):104-116. PMC: 4809063. DOI: 10.1016/j.ccell.2015.12.004. View

Garg G, Yilmaz A, Kumar P, Turkoglu O, Mutch D, Powell M . Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study. Metabolomics. 2019; 14(12):154. DOI: 10.1007/s11306-018-1448-3. View

Lin H, Mahon K, Weir J, Mundra P, Spielman C, Briscoe K . A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. Int J Cancer. 2017; 141(10):2112-2120. DOI: 10.1002/ijc.30903. View

10.

Christen S, Lorendeau D, Schmieder R, Broekaert D, Metzger K, Veys K . Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. Cell Rep. 2016; 17(3):837-848. DOI: 10.1016/j.celrep.2016.09.042. View

11.

Elia I, Doglioni G, Fendt S . Metabolic Hallmarks of Metastasis Formation. Trends Cell Biol. 2018; 28(8):673-684. DOI: 10.1016/j.tcb.2018.04.002. View

12.

Fendt S, Frezza C, Erez A . Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy. Cancer Discov. 2020; 10(12):1797-1807. PMC: 7710573. DOI: 10.1158/2159-8290.CD-20-0844. View

13.

Zhu J, Thompson C . Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019; 20(7):436-450. PMC: 6592760. DOI: 10.1038/s41580-019-0123-5. View

14.

Butler L, Perone Y, Dehairs J, Lupien L, de Laat V, Talebi A . Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159:245-293. PMC: 7736102. DOI: 10.1016/j.addr.2020.07.013. View

15.

Nagarajan S, Butler L, Hoy A . The diversity and breadth of cancer cell fatty acid metabolism. Cancer Metab. 2021; 9(1):2. PMC: 7791669. DOI: 10.1186/s40170-020-00237-2. View

16.

Harayama T, Riezman H . Understanding the diversity of membrane lipid composition. Nat Rev Mol Cell Biol. 2018; 19(5):281-296. DOI: 10.1038/nrm.2017.138. View

17.

Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S . De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010; 70(20):8117-26. DOI: 10.1158/0008-5472.CAN-09-3871. View

18.

Peetla C, Bhave R, Vijayaraghavalu S, Stine A, Kooijman E, Labhasetwar V . Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm. 2010; 7(6):2334-48. PMC: 2997943. DOI: 10.1021/mp100308n. View

19.

Callaghan R, Van Gorkom L, Epand R . A comparison of membrane properties and composition between cell lines selected and transfected for multi-drug resistance. Br J Cancer. 1992; 66(5):781-6. PMC: 1977978. DOI: 10.1038/bjc.1992.360. View

20.

Zong L, Pi Z, Liu S, Xing J, Liu Z, Song F . Liquid extraction surface analysis nanospray electrospray ionization based lipidomics for in situ analysis of tumor cells with multidrug resistance. Rapid Commun Mass Spectrom. 2018; 32(19):1683-1692. DOI: 10.1002/rcm.8229. View